Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-Dense FEC and Docetaxel in High-Risk Breast Cancer
NCT00256360Phase 2Completed
- Sponsor
- UZ Leuven
- Start
- Sep 2005
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pegfilgrastim in breast cancer, sponsored by UZ Leuven. Started Sep 2005; status: completed.
02
Drugs
pegfilgrastim
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00256360.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00256360.